Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an update.
Atomo Diagnostics Ltd. announced that its Pascal test cassette has demonstrated exceptional performance in US clinical studies, supporting a CLIA waiver submission for Lumos’s FebriDx® test. The company has amended its agreement with Lumos to supply Pascal cassettes until 2031, with anticipated orders potentially reaching up to US$6.9 million over the first three years, contingent on the CLIA waiver and minimum order quantities. This development positions Atomo favorably in the US market, with Lumos expecting significant product sales from its agreement with PHASE Scientific.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, focusing on the development and supply of innovative rapid diagnostic test solutions. The company is known for its patented Pascal test cassette, which is used to enhance usability and reliability in point-of-care settings. Atomo is the exclusive licensor, manufacturer, and supplier of the Pascal cassette to Lumos for its FebriDx® product.
Average Trading Volume: 1,460,655
Technical Sentiment Signal: Hold
Current Market Cap: A$16.2M
For an in-depth examination of AT1 stock, go to TipRanks’ Overview page.